These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36035929)

  • 1. Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients.
    Cheng CL; Yen CT; Su CC; Lee CH; Huang CH; Yang YK
    Front Cardiovasc Med; 2022; 9():891606. PubMed ID: 36035929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
    Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
    Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor.
    Foody J; Turpin RS; Tidwell BA; Lawrence D; Schulman KL
    Am Health Drug Benefits; 2017 Nov; 10(8):393-401. PubMed ID: 29263773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
    Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC
    Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat.
    Shin A; Choi SR; Han M; Ha YJ; Lee YJ; Lee EB; Kang EH
    Semin Arthritis Rheum; 2022 Oct; 56():152080. PubMed ID: 35973263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
    Kang EH; Choi HK; Shin A; Lee YJ; Lee EB; Song YW; Kim SC
    Rheumatology (Oxford); 2019 Dec; 58(12):2122-2129. PubMed ID: 31098635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
    Mackenzie IS; Ford I; Nuki G; Hallas J; Hawkey CJ; Webster J; Ralston SH; Walters M; Robertson M; De Caterina R; Findlay E; Perez-Ruiz F; McMurray JJV; MacDonald TM;
    Lancet; 2020 Nov; 396(10264):1745-1757. PubMed ID: 33181081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
    Weisshaar S; Litschauer B; Reichardt B; Gruber F; Leitner S; Sibinovic S; Kossmeier M; Wolzt M
    Rheumatol Int; 2022 Sep; 42(9):1597-1603. PubMed ID: 35589988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
    Wang M; Zhang Y; Zhang M; Li H; Wen C; Zhao T; Xie Z; Sun J
    Ann Palliat Med; 2021 Oct; 10(10):10327-10337. PubMed ID: 34498481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
    White WB; Chohan S; Dabholkar A; Hunt B; Jackson R
    Am Heart J; 2012 Jul; 164(1):14-20. PubMed ID: 22795277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Febuxostat for treating chronic gout.
    Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
    Lertnawapan R; Jatuworapruk K
    Clin Rheumatol; 2021 Jan; 40(1):255-262. PubMed ID: 32607660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
    Ju C; Lai RWC; Li KHC; Hung JKF; Lai JCL; Ho J; Liu Y; Tsoi MF; Liu T; Cheung BMY; Wong ICK; Tam LS; Tse G
    Rheumatology (Oxford); 2020 Sep; 59(9):2340-2349. PubMed ID: 31873735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
    Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
    Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial.
    Ghang BZ; Lee JS; Choi J; Kim J; Yoo B
    RMD Open; 2022 Jun; 8(2):. PubMed ID: 35732345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies.
    Kanbay M; Afsar B; Siriopol D; Dincer N; Erden N; Yilmaz O; Sag AA; Kuwabara M; Cherney D; Rossignol P; Ortiz A; Covic A
    Angiology; 2020 Apr; 71(4):315-323. PubMed ID: 32000517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
    White WB; Saag KG; Becker MA; Borer JS; Gorelick PB; Whelton A; Hunt B; Castillo M; Gunawardhana L;
    N Engl J Med; 2018 Mar; 378(13):1200-1210. PubMed ID: 29527974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.